NCI Research Funding for Leading Cancer Types

(dollars in thousands)

 

FY 2004

FY 2005

FY 2006

FY 2007

 

Actual

Actual

Actual

Estimate

breast

$566,173

$560,052

$584,692

$584,700

prostate

308,517

308,953

293,209

293,200

colon/rectum

261,000

253,140

244,066

244,100

lung

276,549

266,137

242,901

242,900

leukemia

214,745

220,561

223,540

223,500

brain

111,274

107,156

115,154

115,200

non-Hodgkin lymphoma

99,632

106,952

114,116

114,100

melanoma

94,935

102,906

107,955

108,000

ovarian

99,500

97,687

95,106

95,100

pancreas

52,696

66,671

74,208

74,200

liver and biliary tract

63,000

60,502

63,264

63,300

KIDNEY

30,467

32,903

33,413

33,400

multiple myeloma

23,896

28,217

30,306

30,300

bladder

35,083

30,059

24,350

24,400

esophagus

21,694

22,712

21,624

21,600

uterine

27,032

31,055

19,436

19,400

thyroid

9,858

10,650

13,335

13,300

stomach

11,616

11,005

11,542

11,500

Source: Financial Management Branch of the National Cancer Institute

Note: The federal FY (fiscal year) runs from September 1 through August 31

Note: The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget.